MiiS (晉弘科技) Chairman and CEO Cheng Chu-ming stated during a recent investor conference that the company’s heavy R&D and capital investments are now transitioning into mass production and sales. Subsidiaries MiiS Sensing and Lyncée Precision reached break-even points this year. Backed by a strong Q4 peak season, the company expects to reverse its YTD loss of NT$0.68 per share to turn an annual profit. MiiS targets double-digit revenue growth in 2026.

Key Strategic Developments:

• Ophthalmology: A high-end binocular self-imaging OCT (Optical Coherence Tomography) device is currently in the certification phase, with clinical trials underway in the US, Europe, and South America.
• Endoscopy Expansion: MiiS is expanding from soft to rigid endoscopes. Its first rigid arthroscope has applied for US FDA 510(k) and Taiwan TFDA clearance. Approval is expected in Q1 2026 (US) and Q2 2026 (Taiwan).
• Market Share: CDMO business currently accounts for 78% of revenue, while 89% of total sales are exports, primarily to the US. Endoscopes have surged from 12% of revenue in 2024 to an estimated 44% in 2025, becoming the primary growth driver.

Resource: 晉弘未來三年邁收割期，Q4旺季推升全年營運拚轉盈，明年營收成長續航